Cancer registries: a novel alternative to long-term clinical trial follow-up based on results of a comparative study

Abstract

Background Data collection and review were identified as major contributors to the cost of randomized clinical trials (RCTs).

Purpose We proposed and assessed a novel alternative for long-term clinical trial follow-up based on the data captured through an accredited Cancer Registry (CR) that is part of the National Cancer Database (NCDB).

Methods Patients from Mayo Clinic, Rochester, enrolled in the North Central Cancer Treatment Group N934653 (COST) trial (98 patients) and the American College of Surgeons Oncology Group Z0030 trial (55 patients) were included in the study. Demographic, treatment, and long-term outcome data were compared between the hospital-based CR and the RCTs’ databases. Concordances were used to estimate the agreement between two databases. Kaplan—Meier curves were plotted to examine the consistency of time-to-event long-term outcomes of the CR and RCT databases.

Results High concordances (>95%) were observed for most demographic and treatment variables between the CR data and RCT data. The vital status concordances were 100% and 94.5% between the CR and COST and Z0030 databases, respectively. Three discrepant death dates were observed, one in the COST trial and two in the Z0030 trial. The concordances of disease-free status between the CR and RCT databases were 99.0% and 87.3%, and 15 discrepant disease recurrence cases were identified: 4 for COST and 11 for Z0030. Limitations The analysis has been focused on patients from a single site, Mayo Clinic, Rochester, enrolled in two large RCT evaluating surgical treatments. The findings herein need to be confirmed in a broader setting, such as multi-center, multi-registry including nonsurgical trials.

Conclusions CR data were nearly identical to data from two randomized phase III trials in different disease types and conducted by two different cooperative groups. The NCDB Cancer Registries represent a feasible alternative for obtaining long-term follow-up data for large clinical trials. Clinical Trials 2010; 7: 686—695. http:// ctj.sagepub.com

Get full access to this article

View all access options for this article.

References

Emanuel EJ , Schnipper LE , Kamin DY , et al. The costs of conducting clinical research. J Clin Oncol 2003; 21: 4145-50.

Enhancing cancer treatment through improved understanding of the critical components, economics, and barriers of cancer clinical trials: a policy focused guidance document commissioned by C-Change and the Coalition of Cancer Cooperative Groups. 2006. Available at: http://c-changetogether.org/about_ndc/newsroom/article/Cancer%20Clinical%20Trials_Policy.pdf (accessed 7 December 2009).

Improving the Quality of Cancer Clinical Trials Workshop Summary , Institute of Medicine, 2008. Available at: http://www.iom.edu/en/Reports/2008/Improving-the-Quality-of-Cancer-Clinical-Trials-Workshop-Summary.aspx (accessed 7 December 2009).

Multi-Center Phase III Clinical Trials and NCI Cooperative Groups Workshop Summary, Institute of Medicine, 2009 . Available at: http://www.iom.edu/en/Reports/2009/Multi-Center-Phase-III-Clinical-Trials-and-NCI-Cooperative-Groups-Workshop-Summary.aspx (accessed 7 December 2009).

Bilimoria KY , Stewart AK , Winchester DP , Ko CY The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008; 15: 683-90.

The Clinical Outcomes of Surgical Therapy Study Group. a comparison of laparoscopicall assisted and open colectomy for colon cancer. N Engl J Med 2004; 350: 2050-59.

Fleshman J. , Sargent DJ , Green E. , et al. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Ann Surg 2007; 246: 655-62 discussion 662-64.

Allen MS , Darling GE , Pechet TTV , et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, Prospective ACOSOG Z0030 Trial. Ann Thorac Surg 2006; 81: 1013-20.